A review of the in-vitro activity of roxithromycin against genital pathogens.
The in-vitro activity of roxithromycin against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum, Treponema pallidum, Gardnerella vaginalis and Haemophilus ducreyi is reviewed. Roxithromycin demonstrated equivalent activity to erythromycin against N. gonorrhoeae, C. trachomatis, M. hominis, U. urealyticum, G. vaginalis and H. ducreyi. In a rabbit model for syphilis, potentially useful activity against T. pallidum has been demonstrated.
Ridgway
G L
GL
Department of Clinical Microbiology, University College Hospital, London, U.K.
D000818:Animals; D001419:Bacteria / Q000187:drug effects*; D005260:Female; D005835:Genitalia / Q000382:microbiology*; D006801:Humans; D007933:Leucomycins / Q000494:pharmacology*; D008297:Male; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D013587:Syphilis / Q000188:drug therapy
D007933:Leucomycins